FDA Approved: DROXIA — Supplemental Application (Waylis Therapeutics LLC)

View source ↗

Summary

FDA approves a supplemental application for DROXIA (hydroxyurea) submitted by Waylis Therapeutics LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia
• Essential Thrombocythemia
• Polycythemia Vera
• Sickle Cell Disease

Drugs mentioned

• DROXIA (HYDROXYUREA)

Snippet

SUPPL AP for DROXIA (HYDROXYUREA)